ProMIS Neurosciences is trading 5.9% down at $13.41 amid a broader pullback in biotech and risk assets.
- The decline appears tied to sector-wide weakness and cautious market sentiment rather than any new company developments.
- There are no fresh headlines, regulatory filings, or analyst calls as of July 13, 2026, to explain the move.